Know Cancer

or
forgot password

Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study


N/A
19 Years
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study


Although androgens (male hormones) have been the central hypothesis in prostate cancer
etiology for decades, epidemiologic studies in humans have not been able to confirm this
hormonal hypothesis. Most of the studies used sere (blood) to examine the relationships of
circulating hormones with subsequent prostate cancer risk. However, it is possible that
circulating levels of hormones may not reflect intraprostatic and androgenic activity
accurately.

To gain further insights and to provide directions for future epidemiologic studies, the
National Cancer Institute (NCI) is conducting a comprehensive methodological study called
Intraprostatic androgenicity in relation to circulating levels of hormone and polymorphisms
of hormone-related genes: a methodologic study. The specific aims of this study are:

- to correlate circulating levels of androgens and estrogens with tissue levels
(including testosterone, DHT, DHT sulfate, androstenedione, androstanediol glucuronide,
estradiol, estrone, and estrone sulfate);

- to determine whether the serum-tissue correlation is mediated by age, race, and
selected epidemiologic factors, such as smoking and body size;

- to determine whether tissue hormone levels correlate with polymorphisms of certain
hormone-related genes, including androgen receptor (AR) and SRD5A2; and

- to correlate circulating levels of hormones with intraprostatic androgenicity, as
defined by the combined levels of tissue hormones, androgen receptor, and its
associated protein (ARA70).

Inclusion Criteria


- INCLUSION CRITERIA:

Subjects must be over age 18.

Subjects must have a newly diagnosed prostate disease or condition.

Subjects must not currently take hormones.

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

Michael B Cook, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

999999025

NCT ID:

NCT00342433

Start Date:

April 1999

Completion Date:

Related Keywords:

  • Prostate Cancer
  • Correlation
  • Hormones
  • Polymorphism
  • Prostate
  • Tissue
  • Prostatic Neoplasms

Name

Location

University of Oklahoma Health Sciences CenterOklahoma City, Oklahoma  73104
Washington Hospital CenterWashington, District of Columbia  20010
University of California, San FranciscoSan Francisco, California  94143
GW University Medical Center GW Hospital CenterWashington, District of Columbia  20037
Doctors Community HospitalLanham, Maryland  
Fairfax HospitalFalls Church, Virginia  22046